知名学者引用


        除了所发表论文的被引用频次、期刊质量能够彰显学者的学术影响力以外,被知名学者引用也是一项学术评价的重要指标。
        当前同舟云学术认定的知名学者包括:诺贝尔奖、菲尔兹奖、图灵奖等奖项获得者,多个国家的院士,同舟云学术“2023全球学者学术影响力排行版”入榜的前10万学者等。

章星琪 中山大学被知名学者引用:272人次(黄金会员以上可以申请导出本人论文被全部知名学者引用的数据)

1. Emi K. Nishimura 日本 University of Tokyo 2022美国科学院院士 iNOS inhibits hair regeneration in obese diabetic (ob/ob) mice

2. Angela Christiano 美国 Columbia University 2020美国科学院院士 Disease characteristics, clinical evaluation, and new perspectives on pathogenesis

3. James, Judith A. 美国 Oklahoma Medical Research Foundation 2022美国医学院院士 Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a L..

4. Salmon, Jane E. 美国 Hospital for Special Surgery 2016美国医学院院士 Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the ne..

5. Lone,Skov 丹麦 University of Copenhagen Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controll..

6. Brett A,King 美国 Yale University Innovation in Alopecia Areata

7. Linda R,Watkins 美国 University of Colorado An initial investigation of transcutaneous delivery of plasmid DNA encoding interleukin-10 for the t..

8. Eric,Hachulla 法国 University of Lille Cluster analysis of clinical manifestations assigns systemic lupus erythematosus-phenotype subgroups..

9. Luc,Mouthon 法国 University of PARIS 05 Cluster analysis of clinical manifestations assigns systemic lupus erythematosus-phenotype subgroups..

10. Nathalie,Costedoat-Chalumeau 法国 University of PARIS 05 Cluster analysis of clinical manifestations assigns systemic lupus erythematosus-phenotype subgroups..

11. Jerry,Shapiro 美国 New York University Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma..

12. 陆前进 中国 中国医学科学院 主任医师 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus er..

13. Brett A,King 美国 Yale University Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alop..

14. Brett A,King 美国 Yale University Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adu..

15. Rodney,Sinclair 澳大利亚 University of Melbourne Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adu..

16. Emma,Guttman-Yassky 美国 Icahn School of Medicine at Mount Sinai Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adu..

17. 吴小锋 中国 中国科学院 研究生导师 Acrylamides from 1,2-dichloroethane via palladium-catalyzed carbonylation

18. 刘宏民 中国 郑州大学 教授 A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects

19. Jonathan I,Silverberg 美国 George Washington University VINDICATE-P A Mnemonic for the Many Comorbidities of Atopic Dermatitis

20. Martin,Steinhoff 卡塔尔 Qatar University Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritleciti..

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3